Radiotherapy with Tislelizumab and Chemotherapy for Unresectable Lung Cancer
Tests spatial radiotherapy with immunotherapy and chemotherapy in adults with lung cancer.
Key facts
- Who runs it
- Second Affiliated Hospital of Nanchang University
- Where
- Nanchang, ChinaSee the site
- Trial code
- Registry title
- SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 30 people, planned
- Started
- 21 Apr 2025
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Treatments tested
- Spatially Fractionated Radiotherapy (SFRT)
- Tislelizumab, Carboplatin, Pemetrexed
- Tislelizumab, paclitaxel, Carboplatin
- Record updated
- 25 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage III non-small cell lung cancer that doctors judge cannot be removed by surgery at the start.
- Age
- 18 to 85 years
- Sex
- All sexes can join
- Disease stage
- Stage III non-small cell lung cancer (T3-4N1-2M0, 8th edition AJCC) that the multidisciplinary team judges unresectable. Confirmed by tissue or cell tests.
Main reasons for not taking part
- Took part in another study with research products in the past 3 weeks
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- The patient has histologically or cytologically confirmed stage III non-small cell lung cancer (NSCLC) that is deemed unresectable after discussion in the multidisciplinary team (MDT), which is classified as T3-4N1-2M0 according to the 8th edition of the American Joint Committee on Cancer (AJCC)
Who cannot take part
- Has participated in another clinical study using research products within the past 3 weeks
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Where in China
- Nanchang City, Jiangxi ProvinceNanchang, ChinaContact: jing cai Jing CaiTaking people
About the trial
What the trial wants to find out
The aim of this clinical trial is to understand whether spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment is effective in treating initially unresectable stage Ⅲ non-small cell lung cancer (NSCLC). It will also explore the safety of this treatment modality. The main questions it aims to answer are:
Read full original descriptionShow less
Will spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment increase the surgical resection rate of patients with initially unresectable stage Ⅲ non-small cell lung cancer? What adverse reactions will patients experience when receiving spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment?
The group in the trial
- SFRT concurrent with tislelizumab and platinum - based doublet chemotherapyTreatment being tested
SFRT concurrent with immunochemotherapy is given q3w for 3 cycles. Here are details: Radiotherapy: Select several 1 - cm - diameter spherical areas in the primary tumor's hypoxic region, 1.5 - 2 cm apart. Each area receives a single 12 - Gy high - dose radiotherapy, precisely targeting the hypoxic part to enhance the effect. Chemotherapy \& Immunotherapy: 1 - 3 days after radiotherapy, combine 200 mg of tislelizumab with platinum - based doublet chemotherapy. NSCLC chemo - drug combos vary by pathology. For adenocarcinoma, use pemetrexed (500 mg/m² d1) + carboplatin (AUC 5, d1). For other types, use albumin - bound paclitaxel (100 mg/m² d1,8) + carboplatin (AUC 5, d1).
Treatment: Spatially Fractionated Radiotherapy (SFRT), Tislelizumab, Carboplatin, Pemetrexed, and Tislelizumab, paclitaxel, Carboplatin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Spatially Fractionated Radiotherapy (SFRT) Synchronized With Tislelizumab Plus Platinum-based Dual-agent Chemotherapy for Induction Treatment of Initially Unresectable Stage Ⅲ Non-small Cell Lung Cancer: A Clinical Study
- Plain-language title
- Radiotherapy with Tislelizumab and Chemotherapy for Unresectable Lung CancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07131319, who can take part
- Record updated
- 25 June 2026